Harmonic Discovery
Harmonic Discovery is an innovative drug discovery company that leverages machine learning and a proprietary platform to develop next-generation therapeutics. Unlike traditional approaches that target single proteins, Harmonic Discovery embraces disease complexity by engineering rational multi-targeted drugs. Their platform integrates various data types, including protein sequence, structure, and gene expression, to identify molecules that can tune out toxic off-targets and enhance efficacy. The company is built on peer-reviewed science and expertise across medicinal chemistry, cheminformatics, data science, and machine learning. They aim to create medicines that are more efficacious and safer by addressing multiple disease-causing proteins simultaneously.
Harmonic Discovery
Harmonic Discovery is an innovative drug discovery company that leverages machine learning and a proprietary platform to develop next-generation therapeutics. Unlike traditional approaches that target single proteins, Harmonic Discovery embraces disease complexity by engineering rational multi-targeted drugs. Their platform integrates various data types, including protein sequence, structure, and gene expression, to identify molecules that can tune out toxic off-targets and enhance efficacy. The company is built on peer-reviewed science and expertise across medicinal chemistry, cheminformatics, data science, and machine learning. They aim to create medicines that are more efficacious and safer by addressing multiple disease-causing proteins simultaneously.
TL;DR
Founded: 2021
Headquarters / offices: New York, NY; Helsinki, Finland; Tucson, AZ
Focus: Machine-learning driven multi-target drug discovery
Recent funding: Seed $8.0M (Sep 2022)
Notable backers: Innovation Endeavors, Y Combinator, Fifty Years, Caffeinated Capital, Boom Capital Ventures
Company Overview
Problem Domain
Drug discovery for complex diseases using multi-target pharmacology
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
$8,000,000
Reported seed round; Y Combinator participated at an earlier pre-seed stage
Investor Signal
“Backed by a mix of institutional and accelerator investors including Innovation Endeavors and Y Combinator”